Advertisement

Keywords

Major Depressive Disorder Anxiety Disorder Generalize Anxiety Disorder Major Depressive Disorder Post Traumatic Stress Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schwenk TL, Evans DL, Laden SK, Lewis L. Treatment outcome and physicians-patient communication in primary care patients with chronic, recurrent depression. Am J Psychiatry. 2004;161:1892–1901.PubMedCrossRefGoogle Scholar
  2. 2.
    Ornstein S, Stuart G, Jenkins R. Depression diagnoses and antidepressant use in primary care practices. J Fam Pract. 2000;49:68–72.PubMedGoogle Scholar
  3. 3.
    Depression guideline panel. Depression in Primary Care. Clinical Practice Guideline, No. 5. Vol 2. Rockville, MD: Agency for Health Care Policy and Research; April 1993.Google Scholar
  4. 4.
    Mojitabai R. Diagnosing depression and prescribing antidepressants by primary care physicians: the impact of practice style variations. Ment Health Serv Res. 2002;4:109–118.CrossRefGoogle Scholar
  5. 5.
    Weilburg JB, O'Leary KM, Meigs JB, Hennen J, Stafford RS. Evaluation of the adequacy of outpatient antidepressant treatment. Psychiatr Serv. 2003;54: 1233–1239.PubMedCrossRefGoogle Scholar
  6. 6.
    Wilson I, Duszynski K, Mant A. A 5-year follow-up of general practice patients experiencing depression. Fam. Pract. 2003;20:685–689.PubMedCrossRefGoogle Scholar
  7. 7.
    Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient–physician communication. J Am Med Assoc. 2002;288:1403–1409.CrossRefGoogle Scholar
  8. 8.
    Nierenberg AA Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry. 1999;60(suppl 22):7–11.PubMedGoogle Scholar
  9. 9.
    Frank E, Karp JF, Rush AJ. Efficacy of treatments for major depression. Psychopharmacol Bull. 1993;29:457–475.PubMedGoogle Scholar
  10. 10.
    AHCPR. Clinical practice guideline number 5: depression in primary care: treatment of major depression. Vol 2. Rockville, MD: United States Department of Health and Human Services, Agency for Health care Policy and Research; 1993 [AHCPR publication 93–0551].Google Scholar
  11. 11.
    Thase ME, Sullivan LR. Relapse and recurrence of depression: a practical approach for prevention. CNS Drugs. 1995;4:261–277.CrossRefGoogle Scholar
  12. 12.
    Sammons M. Introduction: the politics and pragmatics of prescriptive authority. In: Sammons M, Levant RF, Paige RU, eds. Prescriptive Authority for Psychologists: a History and Guide. Washington, DC: American Psychological Association; 2003:3–31.CrossRefGoogle Scholar
  13. 13.
    Pettit JW, Voelz ZR, Joiner TE. Combined treatments for depression. In: Sammons M, Schmidt NB, eds. Combined Treatments for Medical Disorders. Washington, DC: American Psychological Association; 2001:131–159.CrossRefGoogle Scholar
  14. 14.
    Nemeroff CB, Heim C, Thase ME, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA. 2003;25:14293–14296 [E pub].Google Scholar
  15. 15.
    APA. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text rev. Washington, DC: American Psychiatric Association; 2000.Google Scholar
  16. 16.
    Whooley MA. Simon GE. Managing depression in medical outpatients. NEngl J Med. 2000;343:1942–1950.PubMedCrossRefGoogle Scholar
  17. 17.
    Kjernisted KD. Long-term goals in the management of acute and chronic anxiety disorders. Can J Psychiatry. 2004;49(suppl 1):51S–63S.PubMedGoogle Scholar
  18. 18.
    Perlis RH, Fraguas R, Fava M, et al. Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the sequenced treatment alternatives to relieve depression study. J Clin Psychiatry. 2005;66: 159–166.PubMedCrossRefGoogle Scholar
  19. 19.
    Mulrow CD, Williams Jr JW, Chiquette E, et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med. 2000;108:54–64.PubMedCrossRefGoogle Scholar
  20. 20.
    Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas medication algorithm project. Arch Gen Psychiatry. 2004;61:669–680.PubMedCrossRefGoogle Scholar
  21. 21.
    Lam R, Kennedy SH. Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses. Can J Psychiatry. 2004;49 (suppl 1):17S–26S.PubMedGoogle Scholar
  22. 22.
    Stahl SM. Essential Psychopharmacology of Depression and Bipolar Disorder. Cambridge: Cambridge University; 2000.Google Scholar
  23. 23.
    Green B. Focus on paroxetine. Curr Med Res Opin. 2003;19:13–21.PubMedCrossRefGoogle Scholar
  24. 24.
    Furukawa TA, Streiner DL, Young LT. Antidepressants and benzodiazepine for major depression. Cochrane Database Syst Rev. 2001 [Art. No.: CD001026. DOI:10.1002/14651858.CD001026].Google Scholar
  25. 25.
    Culpepper L. Use of algorithms to treat anxiety in primary care. J Clin Psychiatry. 2003;64(suppl 2):30–33.PubMedGoogle Scholar
  26. 26.
    Kapczinski F, Lima MS, Souza JS, Schmitt R. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev. 2003 [Art. No.: CD003592, DOI:10.1002/14651858.CD003592].Google Scholar
  27. 27.
    Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ. A proposed algorithm for improved recognition and treatment of the depression/anxiety spectrum in primary care. Prim Care Companion J Clin Psychiatry. 2001;3:44–52.PubMedCrossRefGoogle Scholar
  28. 28.
    Fricchione G. Generalized anxiety disorder. N Engl J Med. 2004;351:675–682.PubMedCrossRefGoogle Scholar
  29. 29.
    Stein DJ. Algorithms for primary care: an evidence-based approach to the pharmacology of depression and anxiety disorders. Prim Psychiatry. 2004;11:55–78.Google Scholar
  30. 30.
    Gorman JM. Treating generalized anxiety disorder. J Clin Psychiatry. 2003;64(suppl 2):24–29.PubMedGoogle Scholar
  31. 31.
    Roy-Byrne PP, Wagner AW, Schraufnagel BS. Understanding and treating panic disorder in the primary care setting. J Clin Psychiatry. 2005;66(suppl 4):16–22.PubMedGoogle Scholar
  32. 32.
    Pollack MH. The pharmacotherapy of panic disorder. J Clin Psychiatry. 2005;66(suppl 4):23–27.PubMedGoogle Scholar
  33. 33.
    Kangas M, Henry JL, Bryant RA. Posttraumatic stress disorder following cancer: a conceptual and empirical review. Clin Psychol Rev. 2002;22:499–524.PubMedCrossRefGoogle Scholar
  34. 34.
    Bankier B, Januzzi JL, Littman AB. The high prevalence of multiple psychiatric disorders in stable outpatients with coronary heat disease. Psychosom Med. 2004;66:645–650.PubMedCrossRefGoogle Scholar
  35. 35.
    Stein DJ, Zungu-Dirwayi N, van der Linden GJH, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2000 [Art. No.: CD002795, DOI:10.1002/14651858.CD002795].Google Scholar
  36. 36.
    Albucher RC, Liberzon I. Psychopharmacological treatment in PTSD: a critical review. J Psychiatr Res. 2002;36:355–367.PubMedCrossRefGoogle Scholar
  37. 37.
    Bernard SA, Brera E. Drug interactions in palliative care. J Clin Oncol. 2000;18:1780–1799.PubMedGoogle Scholar
  38. 38.
    Preskorn SH, Flockhart D. Guide to psychiatric drug interactions. Prim Psychiatry. 2004;11:39–60.Google Scholar
  39. 39.
    Preskorn SH, Aldereman J, Chung M, et al. Pharmacokinetics of desipramine co-administered with sertraline or fluoxetine. J Clin Psychopharmacol. 1994;2: 90–98.Google Scholar
  40. 40.
    Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol. 2003;17:517–38.PubMedCrossRefGoogle Scholar
  41. 41.
    Chouinard G, Lefko-Singh K, Teboul E. Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem. Cell Mol Neurobiol. 1999;19:533–552.PubMedCrossRefGoogle Scholar
  42. 42.
    Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part II. Psychosomatics. 2003;44:515–520.PubMedCrossRefGoogle Scholar
  43. 43.
    Preskorn SH. Multiple medications, multiple considerations. J Psychiat Pract. 2001;48–52. http://www.pre3swkorn.com/columns/0101.html; Accessed 07.10.05.
  44. 44.
    Muijsers RB, Plosker GL, Noble S. Sertraline: a review of its use in the management of major depressive disoder in elderely patients. Drugs Aging. 2002;19:377–392.PubMedCrossRefGoogle Scholar
  45. 45.
    Brosen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001; 11:275–283.PubMedCrossRefGoogle Scholar
  46. 46.
    Malin P, Wengel SP, Burke WJ. Escitalopram: better treatment for depression is through the looking glass. Expert Rev Neurother. 2004;4:769–779.PubMedCrossRefGoogle Scholar
  47. 47.
    Crone CC, Gabriel GM. Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. Clin Pharmacokinet. 2004;43:361–94.PubMedCrossRefGoogle Scholar
  48. 48.
    Mulchahey JJ, Malik MS, Sabai M, Kasckow JW. Serotonin-selective reuptake inhibitors in the treatment of geriatric depression and related disorders. Int JNeuropsychopharmacol. 1999;2:121–127.PubMedCrossRefGoogle Scholar
  49. 49.
    Flockhart D. Drug interactions and the cytochrome P450 system: the role of P450 2C19. Clin Pharmacokinet. 1995;29:45–52.PubMedCrossRefGoogle Scholar
  50. 50.
    Ereshefsky L. Treating depression: potential drug–drug interactions. J Clin Psychopharmacol. 1996;16:50S–53S.CrossRefGoogle Scholar
  51. 51.
    Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Int Med 2005;165:1095–1106.CrossRefGoogle Scholar
  52. 52.
    Johnson MD, Newkirk G, White JR. Clinically Significant Drug Interactions; 1999 [Post Grad Med 1999; 105]. http://www.postgradmed.com/issues/1999/0299/johnson.htm; Accessed.
  53. 53.
    Hyttel J.Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol. 1994;9(suppl 1):19–26.PubMedCrossRefGoogle Scholar
  54. 54.
    Fujishiro J, Taiichiro I, Onozawa K, Tsushima M. Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine. Eur J Pharmacol. 2002;454:183–188.PubMedCrossRefGoogle Scholar
  55. 55.
    Masand PS, Gupta S. Long-term side effects of newer generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry. 2002;143:175–182.Google Scholar
  56. 56.
    Dennehy CE, Tsourounis C. Botanical (“herbal medications”) & nutritional supplements. In: Katzung BG, ed. Basic and Clinical Pharmacology. New York: Lange Medical Books/McGraw-Hill;2001:1088–1103.Google Scholar
  57. 57.
    Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St. John's wort. J Psychopharmacol. 2004;18:262–276.PubMedCrossRefGoogle Scholar
  58. 58.
    Young RC, Meyers BS. Psychophramacology. In: Sadovoy J, Lazarus LW, Jarvik LF, etal., eds. Comprehensive Review of Geriatric Psychiatry II. Washington, DC: American Psychiatric Press; 1996:755–817.Google Scholar
  59. 59.
    Julien RM. A Primer of Drug Action. New York: Worth Publishers; 2001.Google Scholar
  60. 60.
    Fiellin DA, Reid C, O'Connor PG. Screening for alcohol problems in primary care. Arch Int Med. 2000;160:1977–1989.CrossRefGoogle Scholar
  61. 61.
    Mayfield D, McLeod G, Hall P. The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry. 1974;131:1121–1123.PubMedGoogle Scholar
  62. 62.
    Zarcone VP. Sleep hygiene. In: Kryger MH, Roth T, Dement WC, eds. Principals and Practice of Sleep Medicine. 3rd ed. Philadelphia: W.B. Saunders Company; 2000:657–661.Google Scholar
  63. 63.
    Carrillo JA, Dahl ML, Svensson JO, etal. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther. 1996;60:183–190.Google Scholar
  64. 64.
    Carrillo JA, Benitez J.Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet. 2000;39: 127–153.Google Scholar
  65. 65.
    Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352: 1112–1120.PubMedCrossRefGoogle Scholar
  66. 66.
    Vitiello B, Swedo S. Antidepressant medications in children. N Engl J Med. 2004;350:1489–1491.PubMedCrossRefGoogle Scholar
  67. 67.
    FDA public health advisory: suicidality in adults being treated with antidepressant medications. http://www.fda.gov/cder/drug/advisory/SSRI200507.htm; Accessed 23.12.05.
  68. 68.
    Yerevanian BI, Koek RJ, Feusner JD, Hwang S, Mintz J.Antidepressants and suicidal behavior in unipolar depression. Acta Psychiatr Scand. 2004;110:452–458.Google Scholar
  69. 69.
    Fava GA. Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry. 2003;64:123–133.PubMedGoogle Scholar
  70. 70.
    Barak Y, Olmer A, Aizenberg D. Antidepressants reduce the risk of suicide among elderly depressed patients. Neuropsychopharmacology. 2006;31: 178–181.PubMedGoogle Scholar
  71. 71.
    Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: Systematic review of randomized controlled clinical trials. BMJ. 2005;330:396.PubMedCrossRefGoogle Scholar
  72. 72.
    Lenzer J.FDA warns that antidepressants may increase suicidality in adults. BMJ. 2005;331:70.Google Scholar
  73. 73.
    Zajecka J, Tracy KA, Mitchell S. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. J Clin Psychiatry. 1997;58:291–297.PubMedGoogle Scholar
  74. 74.
    Berigan TR, Cannard AW, Cannard KR. Transient paroxysmal, shock-like paresthesias associated with paroxetine initiation. J Clin Psychiatry. 1997;58: 175–76.PubMedGoogle Scholar
  75. 75.
    Hu XH, Bull SA, Hunkeler EM, etal. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: Patient report versus physician estimate. J Clin Psychiatry. 2004;65:959–965.Google Scholar
  76. 76.
    Landén M, Högberg B, Thase ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. J Clin Psychiatry 2005;66:100–106.PubMedCrossRefGoogle Scholar
  77. 77.
    Schulberg HC, Katon W, Simon GE, Rush AJ. Treating major depression in primary care practice. Arch Gen Psychiatry. 1998;55:1121–1127.PubMedCrossRefGoogle Scholar
  78. 78.
    Stahl SM. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. New York: Cambridge University Press; 2000.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Personalised recommendations